The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.

Authors :: Verma, Subodh
McMurray, John J.V.
Source :: Circulation. 5/28/2019, Vol. 139 Issue 22, p2537-2541. 5p.
Publication Year :: 2019
Abstract: The authors discuss the serendipitous story of sodium-glucose transporter 2 (SGLT2) inhibitors and heart failure that stems from the Empaglifozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients trial. Highlights include the efficacy of dapagliflozin based on ejection fraction, mechanisms to mediate the cardiorenal benefits of SGLT2 inhibitors, and the use of an SGLT2 inhibitor as part of routine secondary prevention.